content_top
34 companies, 1 interpreter! Insight, foresight
and recommendation
and recommendation
Fate Therapeutics, Inc. (FATE)
-0.11
(-11.00%)
content_middle
Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
FATE’s immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors.
FATE's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.
Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells.
Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Previous Close:
1.32
Open:
4.12
Bid:
3.56
Ask:
4.80
1yr Target Price:
7.67
Day's Range:
3.99 - 4.29
52wk Range:
0.66 - 5.92
Volume:
328156
Average Daily Volume:
286267
Market Capitalization:
0.00M
Trailing Annual Dividend Yield:
N/A
Shares Outstanding:
0.00M
content_right
- December 3, 2024 - 4:32pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q3
- March 19, 2024 - 10:39am | Out and About, Research Notes, Out and About, Financings
- February 20, 2024 - 11:49am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q3
- August 18, 2023 - 4:09pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings
- July 31, 2023 - 7:19am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q2
- May 27, 2023 - 12:37pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q1
- April 10, 2023 - 4:40pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
- August 16, 2022 - 11:38am | Out and About, Research Notes, Out and About
- May 3, 2022 - 10:45am | Out and About, Research Notes, Out and About
- April 26, 2022 - 1:14pm | Out and About, Out and About
- February 17, 2022 - 10:03am | Out and About, Research Notes, Out and About
- February 8, 2022 - 8:07am
- September 23, 2021 - 7:10pm | Out and About, Research Notes, Out and About, Earnings Q2
- January 6, 2021 - 11:46am | Out and About, Research Notes, Out and About, Financings
- June 11, 2020 - 7:05pm | Out and About, Out and About, Financings
- May 30, 2020 - 9:44am | Out and About, Research Notes, Out and About, Earnings Q1
- April 11, 2020 - 1:23pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
- November 3, 2019 - 2:45pm | Out and About, Research Notes, Out and About, Earnings
- September 21, 2018 - 8:13am | Out and About, Out and About, Financings
- September 11, 2018 - 1:18pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q2